Business
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approachesPhase 1 initiation expected in the second half of 2026 NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced clearance of an investigational new drug (IND)
About this update from Arrivent Biopharma, Inc.
[{"type":"image","alt":"ArriVent BioPharma, Inc.","displaySize":"","headline":null,"caption":"ArriVent BioPharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":54,"url":"https://media.zenfs.com/en/globenewswire.com/ee721b323366bda6b0e387ffd6ff88f3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8zcf8leSlIcxxrjSGc1pJA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc2/https://media.zenfs.com/en/globenewswire.com/ee721b323366bda6b0e387ffd6ff88f3","width":300,"height":54},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/8zcf8leSlIcxxrjSGc1pJA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc2/https://media.zenfs.com/en/globenewswire.com/ee721b323366bda6b0e387ffd6ff88f3","width":300,"height":54}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approaches","length":146,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 1 initiation expected in the second half of 2026","length":54,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":200,"olType":false},{"type":"text","content":"NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ARR-002, a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate (ADC) with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors.","length":584,"tagName":"p"},{"type":"text","content":"“We are pleased to advance ARR-002 into the clinic as the second next-generation ADC from our portfolio,” said Stuart Lutzker, MD, Ph.D., President of Research and Development of ArriVent. “At AACR, compelling preclinical data was presented demonstrating ARR-002’s potential to improve safety and efficacy over conventional single-target and bivalent bispecific ADCs in ovarian and endometrial cancers. ARR-002’s dual-target approach is designed to improve delivery and reduce off-tumor toxicity to overcome key limitations of single-target ADCs, including limited...